Thirty Patients Treated to date; Phase II Plan Under Development

Company Expects to Release “Top Line” Interim Data by Year End

Advanced Cell Technology, Inc. (“ACT”; OTC:ACTC or the “Company”), a leader in the field of regenerative medicine, announced today third quarter financial results for the period ended September 30, 2013 and provided an update on their clinical and pre-clinical programs.

Highlights from the third quarter include:

• Received Data Safety Monitoring Board (“DSMB”) Approval to complete the third cohort, which entails finishing the enrollment and treatment of the remaining two patients, in each of the Company’s three ongoing clinical trials with the higher dosage of retinal pigment epithelial (“RPE”) cells derived from human embryonic stem cells (hESCs). Patients in the third cohort were injected with 150,000 hESC-derived RPE cells, consistent with the trial protocols for the treatment of dry Age related Macular Degeneration (“AMD”) and Stargardt’s Macular Dystrophy (“SMD”). This positive evaluation by the DSMB signifies that this dosage level, which is 50% greater than that of the previous cohort, was found to lack significant adverse events.
• Filed an Investigational New Animal Drug (“INAD”) application with the Food and Drug Administration (“FDA”) to tests its proprietary “off-the-shelf” pluripotent stem cell-derived mesenchymal stem cells (“MSC”) in a range of different disease indications. The Company believes these studies are synergistic with its pre-clinical programs which are targeting therapies in humans and also provide the Company with an opportunity to evaluate whether there is a development path in the veterinary therapeutics market.

2013 Third Quarter Financial Results

ACT recognized revenue of approximately $39,000 for the three months ended September 30, 2013 compared with approximately $68,000 in the period a year earlier. The revenue relates to license fees and royalties collected in prior years, which are being amortized over the period of the license granted. Research and Development (“R&D”) expenses for the three months ended September 30, 2013 were approximately $2.9 million, compared to approximately $2.4 million for the same period in 2012. R&D expenses increased compared to the previous year’s third quarter due primarily to higher personnel costs associated with the Company’s pre-clinical and ongoing clinical trial activities. General and Administrative (“G&A”) expenses for the three months ended September 30, 2013 were approximately $3.2 million, compared to approximately $2.7 million for the same period in 2012. The increase was primarily due to an increase in legal fees incurred as the Company works to resolve its non-routine legal issues. Also contributing to the increase in G&A spending was an increase in employee costs as the Company expanded its workforce in 2013, as compared to 2012.

The Company reported a loss from operations of approximately $(6.1) million for the three months ended September 30, 2013, compared to a loss from operations of approximately $(5.0) million in the 2012 third quarter. ACT reported a net loss of approximately $(5.7) million or $(0.00) loss per share in the 2013 third quarter, compared to a net loss of approximately $(8.5) million or $(0.00) loss per share in the same period a year ago.

Net cash used in operating activities for the three months ended September 30, 2013 was $4.9 million, compared to net cash used in operations of $3.8 million for the same period in 2012. The increase in net cash used in operations was a result of higher operating losses, as explained above. The Company ended the 2013 third quarter with cash and cash-equivalents of approximately $5.5 million, compared to $7.2 million at December 31, 2012.

“We are pleased with the progress that we made this quarter on all fronts of the business. Most notably, we continued to advance our AMD and SMD trials. We’ve now treated 30 patients and we continue to be encouraged by the safety profile of our novel cell therapy,” said Gary Rabin, Chief Executive Officer. “ACT is in the fortunate position of working with many of the leading retinal specialists in the world. To have their support, and access to their expertise, as we progress through Phase I, with an eye toward Phase II design, is an invaluable asset for our Company. We believe our Phase I data is very instructive for designing our Phase II studies. We remain steadfastly committed to the clinical development of this potentially curative treatment for AMD and SMD and the millions of patients who suffer from these degenerative diseases.”

Conference Call and Webcast:

The Company will hold a conference call at 4:30 EST today, November 12, during which it will discuss third quarter 2013 results and provide a corporate update. Interested parties may dial (888) 264-3177 and using conference ID 14878582. The call will be available live and for replay by webcast at: http://us.meeting-stream.com/advancedcelltechnology111213.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2012 and its most recent Quarterly Report on Form 10-Q. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

Investors:CEOcast, Inc.Bob Woods, 212-732-4300orPress:Russo PartnersDavid Schull, 858-717-2310